Oncolix, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2016-02: Study NCT02534922; Company role Lead sponsor; Phase Phase 1; Status Unknown.
- 2008-04: Study NCT00671554; Company role Collaborator; Phase Phase 1, Phase 2; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2016-02 | NCT02534922 Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer | Lead sponsor | Phase 1 | Unknown | Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer | 18 | 2019-02 |
| 2008-04 | NCT00671554 Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma | Collaborator Lead: Prisma Health-Upstate | Phase 1, Phase 2 | Terminated Results posted | Melanoma | 3 | 2009-03 |